Tuning the potency and therapeutic window of ImmTAC molecules by affinity modulation
I. B. Robertson, R. M. Mulvaney, N. Dieckmann, A. Vantellini, M. Canestraro, F. Amicarella, R. O'Dwyer, D. K. Cole, S. Harper, O. Dushek, P. Kirk
This paper investigates how altering affinity for target and CD3 affects the potency and specificity of ImmTAC molecules, finding that optimal activation occurs with strong TCR affinity and intermediate anti-CD3 affinity.
bioRxiv · Nov 3, 2022 · PreprintImmunology